Viral variants with altered susceptibility to nucleoside analogs and uses thereof

Viral variants with altered susceptibility to nucleoside analogs and uses thereof

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bartholomeusz, Angeline Ingrid, Locarnini, Stephen Alister, Ayres, Anna, Angus, Peter William, Sievert, William
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Bartholomeusz, Angeline Ingrid
Locarnini, Stephen Alister
Ayres, Anna
Angus, Peter William
Sievert, William
description The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08211633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08211633</sourcerecordid><originalsourceid>FETCH-uspatents_grants_082116333</originalsourceid><addsrcrecordid>eNqNjUEKwjAQAHPxIOof9gOCNSDepeJVEK9lbbbtwpKU7Ebx90bwAZ7mMsMs3fXOGQWemBmjKbzYJkAxyhRAi_Y0Gz9Y2N5gCWLphZJyIMCIkkatDFCUFGyqURrWbjGgKG1-XDk4t7fTZVt0RqM66cb8fXW7475pDt77P5QP6HE5KQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Viral variants with altered susceptibility to nucleoside analogs and uses thereof</title><source>USPTO Issued Patents</source><creator>Bartholomeusz, Angeline Ingrid ; Locarnini, Stephen Alister ; Ayres, Anna ; Angus, Peter William ; Sievert, William</creator><creatorcontrib>Bartholomeusz, Angeline Ingrid ; Locarnini, Stephen Alister ; Ayres, Anna ; Angus, Peter William ; Sievert, William ; Austin Health ; Melbourne Health ; Southern Health</creatorcontrib><description>The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.</description><language>eng</language><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8211633$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,777,799,882,64018</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8211633$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Bartholomeusz, Angeline Ingrid</creatorcontrib><creatorcontrib>Locarnini, Stephen Alister</creatorcontrib><creatorcontrib>Ayres, Anna</creatorcontrib><creatorcontrib>Angus, Peter William</creatorcontrib><creatorcontrib>Sievert, William</creatorcontrib><creatorcontrib>Austin Health</creatorcontrib><creatorcontrib>Melbourne Health</creatorcontrib><creatorcontrib>Southern Health</creatorcontrib><title>Viral variants with altered susceptibility to nucleoside analogs and uses thereof</title><description>The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNjUEKwjAQAHPxIOof9gOCNSDepeJVEK9lbbbtwpKU7Ebx90bwAZ7mMsMs3fXOGQWemBmjKbzYJkAxyhRAi_Y0Gz9Y2N5gCWLphZJyIMCIkkatDFCUFGyqURrWbjGgKG1-XDk4t7fTZVt0RqM66cb8fXW7475pDt77P5QP6HE5KQ</recordid><startdate>20120703</startdate><enddate>20120703</enddate><creator>Bartholomeusz, Angeline Ingrid</creator><creator>Locarnini, Stephen Alister</creator><creator>Ayres, Anna</creator><creator>Angus, Peter William</creator><creator>Sievert, William</creator><scope>EFH</scope></search><sort><creationdate>20120703</creationdate><title>Viral variants with altered susceptibility to nucleoside analogs and uses thereof</title><author>Bartholomeusz, Angeline Ingrid ; Locarnini, Stephen Alister ; Ayres, Anna ; Angus, Peter William ; Sievert, William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_082116333</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Bartholomeusz, Angeline Ingrid</creatorcontrib><creatorcontrib>Locarnini, Stephen Alister</creatorcontrib><creatorcontrib>Ayres, Anna</creatorcontrib><creatorcontrib>Angus, Peter William</creatorcontrib><creatorcontrib>Sievert, William</creatorcontrib><creatorcontrib>Austin Health</creatorcontrib><creatorcontrib>Melbourne Health</creatorcontrib><creatorcontrib>Southern Health</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bartholomeusz, Angeline Ingrid</au><au>Locarnini, Stephen Alister</au><au>Ayres, Anna</au><au>Angus, Peter William</au><au>Sievert, William</au><aucorp>Austin Health</aucorp><aucorp>Melbourne Health</aucorp><aucorp>Southern Health</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Viral variants with altered susceptibility to nucleoside analogs and uses thereof</title><date>2012-07-03</date><risdate>2012</risdate><abstract>The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_08211633
source USPTO Issued Patents
title Viral variants with altered susceptibility to nucleoside analogs and uses thereof
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T15%3A17%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Bartholomeusz,%20Angeline%20Ingrid&rft.aucorp=Austin%20Health&rft.date=2012-07-03&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08211633%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true